Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfer factor as a therapy for multiple sclerosis: a follow-up study.

J A Frith, J G McLeod, A Basten

    Clinical and Experimental Neurology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Multicenter, Phase 1, Open Prospective Trial of Gastric Electrical Stimulation for the Treatment of Obesity: First-in-Human Results with a Novel Implantable System.

    Obesity surgery·2020
    Same author

    Long-term positive psychological outcomes in an Australian pancreatic cancer screening program.

    Familial cancer·2019
    Same author

    Theory of rotational columnar structures of soft spheres.

    Physical review. E·2019
    Same author

    Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation.

    Translational psychiatry·2014
    Same author

    Occupational exposure and risk of central nervous system demyelination.

    American journal of epidemiology·2013
    Same author

    The role of B cells in transplantation and immunopathic diseases.

    Immune network·2010

    Transfer Factor (TF) treatment slowed the progression of multiple sclerosis (MS) in a long-term study. Early and continued TF therapy demonstrated sustained benefits in managing MS disability.

    Area of Science:

    • Neuroimmunology
    • Clinical Neurology
    • Immunotherapy

    Background:

    • Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
    • Current MS treatments aim to reduce disease activity and slow progression.
    • The potential of Transfer Factor (TF) as an immunomodulatory agent for MS requires further investigation.

    Purpose of the Study:

    • To evaluate the long-term efficacy of Transfer Factor (TF) in slowing the progression of multiple sclerosis (MS).
    • To assess the impact of continued TF treatment on disability progression in MS patients.
    • To validate initial findings through a follow-up study and an open-label trial.

    Main Methods:

    • A two-year, double-blind, placebo-controlled trial of TF for MS.

    Related Experiment Videos

  • Longitudinal follow-up of trial participants for up to three years post-trial.
  • An open-label study of 470 patients with clinically definite MS receiving TF treatment.
  • Monitoring disease progression through neurological assessments.

    • Main Results:

    • TF treatment significantly reduced the rate of disability progression in MS patients.
    • Benefits of TF therapy became apparent after 18 months of treatment.
    • Patients continuing TF treatment showed a consistently slower progression rate compared to placebo.
    • Open-label study results corroborated the efficacy of TF in slowing MS progression.

    Conclusions:

    • Transfer Factor (TF) demonstrates a significant effect in slowing the course of multiple sclerosis (MS).
    • Sustained TF treatment is associated with reduced disability progression in MS.
    • TF represents a potential therapeutic option for managing multiple sclerosis.